Screening method
By evaluating the expression level of LRRN4 in mesothelial cells treated with candidate substances, the method addresses the challenge of quantifying epithelial-mesenchymal transition and identifies effective therapeutic agents for diseases like ovarian cancer and endometriosis, enhancing the prevention of disease recurrence.
Patent Information
- Application Number
- PCT/JP2024/017354
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods fail to effectively quantify the degree of epithelial-mesenchymal transition in mesothelial cells and lack specific biomarkers for diseases such as ovarian cancer and endometriosis, making it difficult to identify therapeutic agents that inhibit this transition.
The method involves treating mesothelial cells with a candidate substance and evaluating the expression level of LRRN4, a gene specific to epithelial-to-mesenchymal transition, to determine its inhibitory activity and potential effectiveness in preventing or ameliorating diseases caused by peritoneal dissemination of ectopic cells.
This approach allows for the identification of substances that can inhibit epithelial-to-mesenchymal transition, thereby potentially preventing the recurrence of ovarian cancer or worsening of endometriosis by increasing LRRN4 expression in mesothelial cells.
Smart Images

Figure JP2024017354_14112024_PF_FP_ABST
Abstract
Description
Screening Method
[0001] The present invention relates to a method for screening for a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells, and a method for predicting the risk of developing or aggravating the disease or symptom.
[0002] The peritoneum is a membranous tissue that covers all abdominal organs and is in contact with many tissues, and its relationship to various diseases has been reported. Furthermore, mesothelial cells are the main cells that make up the peritoneum, and the properties of these cells are thought to be involved in the progression and exacerbation of various diseases involving the peritoneum, such as solid cancers such as ovarian, gastric, colon, and pancreatic cancer, as well as the adhesion and proliferation of ectopic cells, such as endometriosis, which is not a malignant tumor.
[0003] Meanwhile, advances in gynecological medical technology have steadily improved the treatment outcomes for ovarian cancer, with the five-year survival rate for ovarian cancer being not low at all, at 90% for stage I, 70% for stage II, 45% for stage III, and 30% for stage IV, depending on the stage of the cancer. However, it is said that more than half of ovarian cancer cases will recur, and in particular, in advanced cancer, approximately half will metastasize or recur within two years, and approximately 70% will metastasize or recur within five years. Furthermore, the survival period after recurrence is said to be approximately two years, and it is difficult to cure after recurrence, and the prognosis for ovarian cancer after recurrence is said to be extremely poor.
[0004] Recent studies have revealed that epithelial-mesenchymal transition (EMT) of mesothelial cells is the cause of ovarian cancer metastasis and poor prognosis. This suggests that normal mesothelial cells, which have an epithelial phenotype, undergo a shift in their properties from epithelial to mesenchymal for some reason, and that this transformation makes ovarian cancer cells more likely to adhere to and / or invade the peritoneum, leading to recurrence (Non-Patent Document 1).
[0005] Meanwhile, according to population estimates by the Statistics Bureau of the Ministry of Internal Affairs and Communications, the estimated number of actual patients with dysmenorrhea, a precursor to endometriosis, is 8 to 10 million, of which the estimated number of patients with endometriosis, a condition in which symptoms have worsened, is 2 to 4 million. Although they are not fatal malignant tumors like ovarian cancer, dysmenorrhea and endometriosis are common diseases affecting many women, and according to a report by the National Trade Union Confederation, work losses due to menstrual symptoms amount to 491.1 billion yen.
[0006] Recent studies have shown that epithelial-mesenchymal transition (EMT) of mesothelial cells is also involved in the pathogenesis of endometriosis. This suggests that normal mesothelial cells, which have an epithelial phenotype, can convert their properties to mesenchymal, which facilitates the adhesion and / or proliferation of endometrial cells to the peritoneum, leading to the development of endometriosis (Non-Patent Document 2).
[0007] Masato Yoshihara et al. Int. J. Cancer: Vol.146, pp.2268-2280, 2020Young VJ et al. Human Reproduction Update, Vol.19, No.5 pp.558-569, 2013
[0008] As described above, peritoneal mesothelial cells are important cells that greatly affect a woman's life or quality of life, and it can be said that the epithelial-mesenchymal transition of these mesothelial cells is the causative mechanism of these diseases. The present inventors believed that inhibitors of this epithelial-mesenchymal transition could be used as therapeutic agents for these diseases.
[0009] However, it is difficult to quantify the degree of epithelial-mesenchymal transition of mesothelial cells from cell morphology, and no biomarkers specific to epithelial-mesenchymal transition of mesothelial cells were known.
[0010] In view of the above-mentioned problems, the present inventors conducted extensive research and found that LRRN4 is a gene specific to the epithelial-mesenchymal transition of mesothelial cells, and the expression level of which varies depending on the degree of epithelial-mesenchymal transition. By assessing the expression level of this gene, it is possible to evaluate the risk of developing or aggravating ovarian cancer or endometriosis.
[0011] Furthermore, the present inventors have discovered a method for determining whether a component to be evaluated has epithelial-mesenchymal transition inhibitory activity or mesenchymal-epithelial transition activity in mesothelial cells, and thus whether it is effective in suppressing the recurrence of ovarian cancer or the worsening of endometriosis, by artificially inducing epithelial-mesenchymal transition in mesothelial cells to reduce the expression level of LRRN4 (abnormalization of mesothelial cells), administering a candidate substance to be evaluated to the cells, and evaluating whether the reduced LRRN4 expression increases (normalization of mesothelial cells), thereby completing the present invention.
[0012] That is, in one preferred aspect of the present invention, there is provided the following screening method: [1] A method for screening for a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells, comprising the steps of: (a) treating mesothelial cells with a candidate substance; (b) confirming the expression or activity level of LRRN4 (Leucine Rich Repeat Neuronal 4) in the mesothelial cells; and (c) selecting the candidate substance as a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells, when the expression or activity level of LRRN4 in the mesothelial cells increases compared to before the treatment.
[0013] [2] The method according to [1], wherein the disease or symptom caused by peritoneal dissemination of ectopic cells is metastasis of cancer cells to the peritoneum.
[0014] [3] The method according to [2], wherein the metastasis of cancer cells to the peritoneum occurs in at least one solid cancer selected from the group consisting of ovarian cancer, gastric cancer, colon cancer, and pancreatic cancer.
[0015] [4] The method according to any one of [1] to [3], wherein the disease or symptom caused by peritoneal dissemination of ectopic cells is a disease or symptom caused by adhesion or growth of endometrial cells to the peritoneum.
[0016] [5] The method according to [4], wherein the disease or symptom caused by adhesion or growth of endometrial cells to the peritoneum is menstrual pain, functional dysmenorrhea, organic dysmenorrhea, or endometriosis.
[0017] [6] The method according to any one of [1] to [5], wherein the mesothelial cells have a lower expression of LRRN4 than normal mesothelial cells.
[0018] [7] The method according to any one of [1] to [6], wherein the mesothelial cells are mesothelial cells in which mesenchymal transition has been induced by administering a cytokine to normal mesothelial cells.
[0019] [8] The method according to [7], wherein the cytokine is TGF-β.
[0020] In another preferred embodiment of the present invention, there is provided a risk prediction method as described below: A method for predicting the risk of developing or aggravating a disease or symptom caused by peritoneal dissemination of ectopic cells, comprising the steps of: (a) confirming the expression or activity level of LRRN4 in mesothelial cells obtained from a subject; and (b) determining that the subject has a high risk of developing or aggravating a disease or symptom caused by peritoneal dissemination of ectopic cells, when the expression or activity level of LRRN4 in mesothelial cells obtained from the subject is lower compared to the expression or activity level of LRRN4 in normal mesothelial cells.
[0021] By evaluating the expression or activity level of LRRN4, which is specific to epithelial-mesenchymal transition of mesothelial cells and whose expression level varies depending on the degree of epithelial-mesenchymal transition, it is possible to evaluate the risk of contracting or aggravating diseases or symptoms caused by peritoneal dissemination of ectopic cells, and to screen for substances that may be agents for preventing or ameliorating these diseases or symptoms.
[0022] FIG. 1 is a photograph showing the morphology of normal mesothelial cells and mesothelial cells in which mesenchymal transition was induced in Test Example 2. FIG. 2 is the result of Western blotting showing changes in αSMA, Smad2, and pSmad2 in normal mesothelial cells, mesothelial cells in which mesenchymal transition was induced with TGF-β, and mesothelial cells treated with a TGF-β inhibitor in Test Example 2. FIG. 3 is a photograph showing the localization of LRRN4 in mesothelial cells in Test Example 4. FIG. 4 is the result of 3D image analysis showing the effect of mesothelial cells that have undergone epithelial-mesenchymal transition on peritoneal dissemination of ectopic cells in Test Example 4. FIG. 5 is the result showing the function of LRRN4 in human mesothelial cells in Test Example 4. FIG. 6 is the result of quantification of LRRN4 mRNA expression levels in various cell lines and human mesothelial cells in Test Example 5. FIG. 7 is a photograph showing morphological changes before and after mesenchymal transition in a human normal mesothelial cell line in Test Example 5. Figure 8 shows the results of Test Example 5, which show LRRN4 protein expression on human mesothelial cells from patients with uterine leiomyoma, ovarian cancer, and endometriosis. Figure 9 shows the results of Test Example 5, which show changes in LRRN4 protein expression in a human normal mesothelial cell line. Figure 10 shows the results of Test Example 5, which show changes in LRRN4 protein expression in human peritoneal mesothelial cells when hypoxic conditions are applied. Figure 11 shows the results of Test Example 5, which evaluate the effect of a candidate substance on mesenchymal-epithelial transition when it is applied to a mesothelial cell line. Figure 12 shows the results of Test Example 5, which evaluate the effect of a candidate substance on mesenchymal-epithelial transition when it is applied to a mesothelial cell line. Figure 13 shows the results of Test Example 6, which evaluate the effect of a candidate substance on mesenchymal transition and peritoneal dissemination of ectopic cells when it is applied to a mesothelial cell line. Figure 14 shows the results of evaluating the effects of candidate substances on mesenchymal transition and peritoneal dissemination of ectopic cells when they are allowed to act on a mesothelial cell line in Test Example 6. Figure 15 shows the results of evaluating the effects of candidate substances on mesenchymal transition and peritoneal dissemination of ectopic cells when they are allowed to act on a mesothelial cell line in Test Example 6.
[0023] [Method for screening for a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells] The present invention provides a method for screening for a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells, the method comprising the following steps: (a) treating mesothelial cells with a candidate substance; (b) confirming the expression or activity level of LRRN4 (Leucine Rich Repeat Neuronal 4) in the mesothelial cells; and (c) selecting the candidate substance as a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells, when the expression or activity level of LRRN4 in the mesothelial cells increases compared to before the treatment.
[0024] As used herein, the term "peritoneum" refers to a thin, translucent membrane located in the peritoneal cavity that covers intraperitoneal organs (abdominal organs). The peritoneum is composed of a mesothelial cell layer covering the outer surface and a submesothelial layer (connective tissue layer) that is connective tissue. Fibroblasts are primarily present in the submesothelial layer, and collagen fibers and mucopolysaccharides exist as extracellular matrices. Numerous capillaries and lymphatic vessels are also formed in a network in the submesothelial layer. Organs within the peritoneum include digestive organs such as the stomach, small intestine, large intestine, liver, and gallbladder, as well as female genitalia such as the fallopian tubes and uterus.
[0025] As used herein, the term "ectopic cells" refers to cells that do not naturally exist in the peritoneum, and includes, but is not limited to, cells that are different from mesothelial cells, such as cancer cells, endometrial cells, and cells derived from other organs that contact the peritoneum.
[0026] When cancer develops and grows in the peritoneal organs, cancer cells may break away from the organ, invade the peritoneal cavity, adhere to the peritoneum, and grow through repeated cell division to form a tumor. In the case of endometriosis, endometrial cells may break away from the organ, invade the peritoneal cavity, adhere to the peritoneum, and grow through repeated cell division. This adhesion and growth of ectopic cells to the peritoneum is called "peritoneal dissemination of ectopic cells."
[0027] As mentioned above, the properties of mesothelial cells are thought to be involved in the progression and exacerbation of various diseases involving the peritoneum, and the present inventors have clarified that mesothelial cells that have undergone epithelial-mesenchymal transition (EMT) are responsible for promoting peritoneal dissemination of ectopic cells.
[0028] As used herein, "diseases or symptoms caused by peritoneal dissemination of ectopic cells" include, but are not limited to, ovarian cancer, gastric cancer, colon cancer, pancreatic cancer, menstrual pain, primary dysmenorrhea, organic dysmenorrhea, endometriosis, menstrual discomfort, etc. In another embodiment, "diseases or symptoms caused by peritoneal dissemination of ectopic cells" may be abdominal symptoms caused by peritoneal dissemination of ectopic cells, including, for example, abdominal distension, constipation, abdominal pain, nausea, vomiting, etc.
[0029] Dysmenorrhea is classified into functional (primary) dysmenorrhea and organic (secondary) dysmenorrhea. Functional (primary) dysmenorrhea is when no organic disease is found in the pelvis, and more than 90% of dysmenorrhea cases are functional (primary) dysmenorrhea.
[0030] Examples of unpleasant conditions associated with menstruation include physical or mental conditions such as lower abdominal pain, lower back pain, abdominal distension, headache, nausea, anemia, dizziness, diarrhea, fatigue, lethargy, depression, emotional instability (irritability, etc.), decreased concentration, drowsiness, breast tenderness (mastalgia), lower abdominal bloating, swelling, stiff shoulders, rough skin, decreased appetite, increased appetite, decreased efficiency, cold sweats, weight gain, and at least one selected from the group consisting of conditions that interfere with daily life. In this specification, these unpleasant conditions can also be referred to as discomfort before or during menstruation. Menstrual discomfort may also be experienced as heaviness in the lower abdomen, discomfort in the lower abdomen, discomfort throughout the abdomen, heaviness throughout the body, discomfort like tightness (discomfort), a pinching sensation in the abdomen, a heavy back, or a feeling of being unable to move.
[0031] (a) Step of treating mesothelial cells with a candidate substance) In the (a) step of treating mesothelial cells with a candidate substance, the method is not particularly limited and can be any known method as long as it can bring the candidate substance into contact with the mesothelial cells. Although not limited thereto, step (a) may be performed in vitro, for example, by culturing mesothelial cells in vitro and adding the candidate substance. The candidate substance can be added to the medium at a final concentration of, for example, 0.1 μM to 100 μM. The cell culture method is not particularly limited, and may be two-dimensional culture or three-dimensional culture.
[0032] Treatment with the candidate substance can be carried out, for example, after about 1 to 10 days.
[0033] As used herein, the term "candidate substance" is not particularly limited, and examples thereof include nucleotides, DNA, RNA, amino acids, aptamers, proteins, chemical compounds, natural products, and natural extracts.
[0034] The mesothelial cells to be used may be an established mesothelial cell line or primary cultured mesothelial cells.
[0035] Here, when it is desired to confirm an increase in the expression or activity level of LRRN4, it is also preferable, but not limited to, that the mesothelial cells be those that express LRRN4 at a lower level compared to normal mesothelial cells.
[0036] Mesothelial cells that express LRRN4 at a lower level than normal mesothelial cells may be a mesothelial cell line that has been established while retaining the property, or may be mesothelial cells in which epithelial-mesenchymal transition (EMT) has been induced in normal mesothelial cells.
[0037] The method for inducing epithelial-mesenchymal transition (EMT) in normal mesothelial cells is not particularly limited and can be performed by known methods. For example, mesenchymal transition can be induced by administering cytokines to normal mesothelial cells.
[0038] Examples of cytokines used in methods for inducing epithelial-mesenchymal transition (EMT) in normal mesothelial cells include TGF-β.
[0039] Alternatively, normal mesothelial cells, a substance that induces epithelial-mesenchymal transition, and a candidate substance can be placed in a medium and cultured together for treatment.
[0040] (b) confirming the expression or activity level of LRRN4 (Leucine Rich Repeat Neuronal 4) in the mesothelial cells) The present inventors have found that LRRN4 is expressed in normal mesothelial cells and disappears in mesenchymal-transitioned mesothelial cells. The molecular function of LRRN4, which is expressed specifically in normal mesothelial cells in the peritoneal cavity, has remained largely unexplored. The present inventors have confirmed that an LRRN4 inhibition experiment in mesothelial cells using siRNA increased cell migration ability compared to controls, and that LRRN4 is localized at cell-cell adhesion sites by cell immunostaining. Therefore, LRRN4 can be a marker for normal mesothelial cells as well as a sensitive negative marker for mesenchymal-transitioned mesothelial cells.
[0041] The method for confirming the expression or activity level of LRRN4 is not particularly limited and can be performed by known methods, and examples include methods for confirming the presence or absence of LRRN4 protein or mRNA encoding it, and the expression level or activity level, and methods for confirming the amount or activity level of the protein or mRNA encoding it using a molecule that specifically binds to the LRRN4 protein or the mRNA encoding it.
[0042] Methods for confirming the expression or activity level of LRRN4 protein include, but are not limited to, Western blot, enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay, complement fixation assay, FACS, and protein chip.
[0043] Methods for confirming the expression or activity level of mRNA encoding the LRRN4 protein include, but are not limited to, reverse transcriptase polymerase reaction (RT-PCR), competitive reverse transcriptase polymerase reaction (competitive RT-PCR), real time polymerase reaction (real time RT-PCR), real time quantitative RT-PCR, RNase protection method, Northern blotting, and gene chips.
[0044] (c) if the expression or activity level of LRRN4 increases compared to before the treatment, selecting the candidate substance as a substance for preventing or ameliorating diseases or symptoms caused by peritoneal dissemination of ectopic cells) Using the expression or activity level of LRRN4 as an index, it becomes possible to appropriately select candidate substances.
[0045] As described above, the present inventors have found that LRRN4 is expressed in normal mesothelial cells and disappears in mesenchymal-transitioned mesothelial cells. Therefore, substances that increase the expression or activity level of LRRN4 can be used as substances for preventing or ameliorating diseases or symptoms caused by peritoneal dissemination of ectopic cells.
[0046] Whether or not the expression or activity level of LRRN4 is increased compared to before the treatment can be analyzed or compared by known methods. Here, an increase in the expression or activity level of LRRN4 may mean, for example, that the rate of increase in the expression or activity level of LRRN4 is at least 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 11% or more, 12% or more, 13% or more, 14% or more, 15% or more, 16% or more, 17% or more, 18% or more, 19% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, etc.
[0047] Candidate substances selected as described above using the expression or activity level of LRRN4 as an index can be used as agents for preventing or ameliorating diseases or symptoms caused by peritoneal dissemination of ectopic cells.
[0048] The above-mentioned preparation can be added to or mixed with pharmaceuticals, foods, beverages, feed, or pet foods. Alternatively, it can be used as is as pharmaceuticals, foods, beverages, feed, or pet foods. Furthermore, the above-mentioned preparation can be used as foods or beverages that explicitly or implicitly claim to have the function of preventing or ameliorating diseases or symptoms caused by peritoneal dissemination of ectopic cells, i.e., health foods, functional foods, foods for patients, and foods for specified health uses. Furthermore, even if the above-mentioned functionality is not explicitly or implicitly claimed, it can be used as a so-called doctor's supplement recommended or suggested by doctors in internal medicine, surgery, veterinary clinics, etc., at hospitals and / or clinics.
[0049] Pharmaceuticals, health foods, functional foods, foods for the sick, and foods for specified health uses can be used in various formulations, such as solid preparations (tablets, orally disintegrating tablets, granules, fine granules, powders, capsules, chewable tablets, candy, etc.), liquid preparations (syrups, suspensions), and liquid foods.
[0050] For example, tablets can be prepared by powdering the selected candidate substance, mixing it with a pharmaceutically acceptable carrier component (such as an excipient), and compressing it into a tablet. Tablets can also be prepared by pouring the powder into a mold. Tablets can also be sugar-coated to form sugar-coated tablets. Furthermore, tablets can be single-layer tablets or layered tablets such as double-layer tablets.
[0051] Powdered granules such as granules may be prepared by various granulation methods (extrusion granulation, pulverization granulation, dry compaction granulation, fluidized bed granulation, tumbling granulation, high-speed stirring granulation, etc.), and tablets can be prepared by an appropriate combination of the above-mentioned granulation methods and tableting methods (wet tableting, direct tableting), etc.
[0052] Capsules can be prepared by filling a capsule (soft or hard capsule) with powder (powder, granules, etc.) by a conventional method.
[0053] The liquid preparation can be prepared by dissolving or dispersing each component in an aqueous medium (purified water, purified water containing ethanol, etc.) which is a carrier component, filtering or sterilizing the resulting mixture if necessary, filling the resulting mixture into a predetermined container, and sterilizing the resulting mixture. The preferred dosage form of the solid preparation of the present invention is a capsule or tablet, and a soft capsule (soft capsule) is more preferred.
[0054] Soft capsules are preferred by users because they have a smooth surface and are easy to swallow. Common methods for manufacturing soft capsules include the flat plate method, the rotary method, and the seamless method.
[0055] In the rotary method (punching method), a sheet-like capsule shell sandwiches the flowing filling material and forms a capsule shape along the holes of a rotating cylindrical mold. On the other hand, in the seamless method (dropping method), the capsule shell composition and the filling material are simultaneously discharged from multiple concentric nozzles to form a seamless capsule shape.
[0056] The base material for the soft capsule shell is not particularly limited, but may be starch, pullulan, cellulose, polyvinyl alcohol, gelatin, succinated gelatin, etc., with starch, gelatin, and succinated gelatin being preferred, and gelatin and succinated gelatin being more preferred. These may be used alone or in combination of two or more.
[0057] The above preparations can also be manufactured as liquid drinks such as soups, juices, fruit juice drinks, milk, dairy drinks, whey drinks, lactic acid bacteria drinks, tea drinks, alcoholic drinks, coffee drinks, carbonated drinks, soft drinks, water drinks, cocoa drinks, jelly drinks, sports drinks, and diet drinks; semi-solid foods such as pudding and yogurt; noodles, confectioneries, spreads, etc.
[0058] When prepared as a food product, various food additives may be added, such as antioxidants, colorings, flavorings, seasonings, sweeteners, acidulants, pH adjusters, quality stabilizers, and preservatives.
[0059] When preparing a pharmaceutical product, it is prepared as a formulation containing the selected candidate substance as an active ingredient and preferably a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier generally refers to an inert, non-toxic, solid or liquid filler, diluent, or encapsulating material that does not react with the active ingredient, such as water, ethanol, polyols, suitable mixtures thereof, vegetable oils, and other solvents or dispersion media.
[0060] Pharmaceuticals are administered orally or parenterally, for example, into the oral cavity, the digestive tract, or the nasal cavity. Orally administered formulations include solid formulations (tablets, orally disintegrating tablets, granules, fine granules, powders, capsules, chewable tablets, candy, etc.) and liquid formulations (syrups, suspensions, inhalants). Parenterally administered formulations include eye drops, drip infusions, nasal drops, and injections. The formulation form is not limited, but is preferably an orally disintegrating tablet, chewable tablet, candy, granules, powder, or liquid formulation from the viewpoint of significantly achieving the effects of the present invention.
[0061] The pharmaceutical may further contain additives commonly used in the pharmaceutical field. Such additives include, for example, excipients, binders, disintegrants, lubricants, antioxidants, coloring agents, flavoring agents, etc., and can be used appropriately as needed. To achieve sustained release for prolonged action, the pharmaceutical may also be coated with a known retardant, etc. The pharmaceutical composition may further contain other additives or drugs, such as antacids and gastric mucosa protectants, as needed.
[0062] The pharmaceuticals can be applied in the form of oral administration, internal administration, etc. The pharmaceuticals can be used therapeutically or non-therapeutically.
[0063] The daily oral intake or administration amount of the selected candidate substance for an adult can be determined appropriately based on the individual's condition, body weight, sex, age, activity of the material, intake or administration route, intake or administration schedule, formulation form, or other factors. The daily oral intake or administration amount of the selected candidate substance for an adult is, for example, preferably 1 to 3,000 mg, more preferably 50 to 2,500 mg, even more preferably 100 to 2,000 mg, even more preferably 100 to 1,500 mg, or even more preferably 200 to 1,500 mg. It may also be 300 to 1,500 mg, 400 to 1,500 mg, 200 to 1,300 mg, 300 to 1,300 mg, 400 to 1,300 mg, or the like.
[0064] The oral intake or dosage of the above formulation for an adult per day may be divided into 1 to 6 capsules, 1 to 4 capsules, 1 to 3 capsules, or 1 to 2 capsules depending on the dosage form.
[0065] The above preparation can be taken or administered once to several times a day, usually 1 to 6 times a day, 1 to 3 times a day, 1 to 2 times a day, or at any period and interval, but once a day is preferred.
[0066] When the above-mentioned preparation is used as feed, pet food, or the like, the target organism is not particularly limited, but is preferably a mammal, reptile, amphibian, bird, or fish, and more preferably a mammal other than humans, such as a platypus, echidna, opossum, quoll, kangaroo, aardvark, rock badger, elephant, armadillo, sloth, anteater, tree shrew, flying lemur, chimpanzee, rabbit, degu, dormouse, squirrel, raccoon, mouse, hedgehog, chinchilla, ferret, camel, wild boar, giraffe, deer, cow, goat, hippopotamus, whale, dolphin, horse, rhinoceros, tapir, bat, monkey, tiger, wolf, weasel, bear, seal, dog, cat, parakeet, parrot, finch, owl, or horned owl, and more preferably a dog or cat.
[0067] When the above preparation is used as feed or pet food, it may be given to the pet several times a day by adding it to the staple food, or it may be given as a snack at any time.
[0068] When the above-mentioned preparation is used as feed, pet food, etc., the daily oral intake or administration amount of the selected candidate substance is, for example, preferably 1 to 150 mg / day / kg body weight, more preferably 3 to 100 mg / day / kg body weight, even more preferably 5 to 80 mg / day / kg body weight, even more preferably 5 to 60 mg / day / kg body weight, and even more preferably 5 to 50 mg / day / kg body weight. The content of the selected candidate substance can be an amount that will result in the above-mentioned intake or administration amount.
[0069] [Method for predicting the risk of developing or worsening a disease or symptom caused by peritoneal dissemination of ectopic cells] In another embodiment, the present invention provides a method for predicting the risk of developing or worsening a disease or symptom caused by peritoneal dissemination of ectopic cells, comprising the following steps: (a) confirming the expression or activity level of LRRN4 in mesothelial cells obtained from a subject; and (b) determining that the subject has a high risk of developing or worsening a disease or symptom caused by peritoneal dissemination of ectopic cells, when the expression or activity level of LRRN4 in mesothelial cells obtained from the subject is lower compared to the expression or activity level of LRRN4 in normal mesothelial cells.
[0070] As described above, the present inventors have elucidated that mesothelial cells that have undergone epithelial-mesenchymal transition (EMT) are responsible for promoting peritoneal dissemination of ectopic cells. In particular, the present inventors have found that LRRN4 is expressed in normal mesothelial cells and disappears in mesothelial cells that have undergone mesenchymal transition. Therefore, the expression or activity level of LRRN4 in mesothelial cells obtained from a subject can be used as an indicator to predict or assist in predicting the risk of a subject developing or developing a disease or symptom caused by peritoneal dissemination of ectopic cells. Various terms and common methods are as described in the "Method for screening substances for preventing or ameliorating diseases or symptoms caused by peritoneal dissemination of ectopic cells."
[0071] (a) Step of confirming the expression or activity level of LRRN4 in mesothelial cells obtained from a subject) Although not limited thereto, step (a) may be performed in vitro, for example, by culturing mesothelial cells obtained from a subject in vitro and using a method similar to that described in the section (b) of [Method for screening for a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells] above.
[0072] (b) determining that the subject is at high risk of developing or worsening a disease or symptom due to peritoneal dissemination of ectopic cells when the expression or activity level of LRRN4 in mesothelial cells obtained from the subject is lower compared to the expression or activity level of LRRN4 in normal mesothelial cells.) In this step, the normal mesothelial cells used may be an established normal mesothelial cell line, or primary cultured normal mesothelial cells.
[0073] A case where the expression or activity level of LRRN4 in mesothelial cells obtained from the subject is lower than that in normal mesothelial cells can be analyzed and compared by known methods, and examples of cases where the rate of decrease in the expression or activity level of LRRN4 is at least 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 11% or more, It can be 12% or more, 13% or more, 14% or more, 15% or more, 16% or more, 17% or more, 18% or more, 19% or more, 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, etc.
[0074] Next, the present invention will be specifically explained with reference to examples and test examples, but the present invention is not limited to the following examples and test examples.
[0075] Test Example 1: Extraction and establishment of mesothelial cells. Human peritoneal mesothelial cells were isolated from unaffected omental tissue to obtain normal mesothelial cells. Mesothelial cells were isolated from the omental tissue of an epithelial ovarian cancer patient by a standard method to obtain ovarian cancer patient-derived mesothelial cells. The mesothelial cells were maintained and cultured on a collagen-coated plate in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and penicillin / streptomycin.
[0076] In addition to the above, commercially available or available strains of mesothelial cells isolated from omentum tissue can also be used. Commercially available products include Cryopreserved Mesothelial Cells DIABETIC DONOR (Zen-Bio) and mesothelial cell line (LP-9). Available strains include ES-2 (RRID: CVCL_3509), SKOV3 (RRID: CVCL_0532), and OV90 (RRID: CVCL_3768) (all available from ATCC (American Type Culture Collection)).
[0077] Test Example 2: Induction of mesenchymal transition in normal mesothelial cells. 1 to 10 ng / mL of TGF-β1 was applied to the above mesothelial cell line in RPMI-1640 medium supplemented with 1% FBS to induce epithelial-mesenchymal transition. After the induction, the mesothelial cell line was αSMA positive, confirming that epithelial-mesenchymal transition was induced through phosphorylation of Smad2. Furthermore, it was confirmed that this effect was negated by a TGF-β receptor inhibitor.
[0078] The results are shown in Figures 1 and 2. In the control group without EMT induction, mesothelial cells exhibited a cobblestone-like morphology (Figure 1, top), but induction of EMT changed the morphology to a spindle-like morphology (Figure 1, bottom).
[0079] Furthermore, Western blotting analysis of αSMA, a mesenchymal cell marker, demonstrated that induction of EMT resulted in the mesothelial cell line changing from αSMA negative to αSMA positive. Furthermore, it was confirmed that phosphorylation of Smad2, a representative downstream factor of TGF-β signaling, was enhanced. Furthermore, it was found that this reaction was inhibited by a TGF-β receptor inhibitor (RI), suppressing EMT (Figure 2).
[0080] Test Example 3 Proteome analysis and measurement of LRRN4 expression level in mesothelial cells Using LC-MS / MS, proteomic analysis was performed on normal peritoneal mesothelial cells and mesothelial cells in which epithelial-mesenchymal transition was induced by TGF-b1 stimulation in the same manner as in Test Example 2. The results are shown in Table 1.
[0081]
[0082] As shown in Table 1, when mesothelial cells in which epithelial-mesenchymal transition was induced by TGF-b1 stimulation were compared with normal peritoneal mesothelial cells, LRRN4 was selected as the protein whose expression was most reduced by the induction of epithelial-mesenchymal transition (protein expression: 180.3-fold decrease). It was confirmed that LRRN4 expression was significantly reduced in mesothelial cells in which mesenchymal transition was induced by TGF-β1 stimulation.
[0083] Test Example 4: LRRN4 expression level in mesothelial cells and effect on peritoneal dissemination of ectopic cells LRRN4 expression in normal mesothelial cells was examined by immunostaining using an LRRN4-specific antibody. The results are shown in Figure 3.
[0084] As shown in Figure 3, LRRN4 is localized on the surface of mesothelial cells, and its expression was also confirmed in human peritoneal mesothelial cells.
[0085] Using a transwell chamber, mesothelial cells (referred to as HPMC) in which EMT was induced were co-cultured with ovarian cancer cells, a type of ectopic cell, for 72 hours, and 3D image analysis was performed. The results are shown in Figure 4. The arrowhead in Figure 4 indicates the mesothelial cells in which EMT was induced.
[0086] As shown in Figure 4, the analysis revealed that mesothelial cells in which epithelial-mesenchymal transition was induced led cancer cells and promoted their invasion. On the other hand, when normal mesothelial cells were co-cultured with cancer cells, no effect of promoting cancer cell invasion was observed.
[0087] Furthermore, when LRRN4 expression in normal mesothelial cells was suppressed by introducing siRNA, migration ability was significantly increased in a transwell migration assay (FIG. 5).
[0088] Test Example 5. Administration of candidate substances to mesenchymal transition-induced mesothelial cells and measurement of changes in LRRN4 expression levels. The expression levels of LRRN4 mRNA in various cell lines and human mesothelial cells were quantified by real-time PCR. The results are shown in Figure 6.
[0089] As shown in Figure 6, the expression level of LRRN4 mRNA was low in ovarian cancer cell lines (ES2, OV90, HEY, SKOV3, OVCR3, KURAMOCHI, TOV-21G, OAW28, NOS2).
[0090] Furthermore, the mRNA expression levels were high in LP-9, a normal human mesothelial cell line, and in non-lesioned human peritoneal mesothelial cells (#15 HPMC).
[0091] As in Test Example 2 above, it was revealed that the level of LRRN4 mRNA expression was reduced in human peritoneal mesothelial cells (#15CAM, #16CAM, #18CAM, #21CAM) in which mesenchymal transition was induced using TGF-β1, compared to normal human peritoneal mesothelial cells without lesions (#15HPMC, #16HPMC, #18HPMC, #21HPMC).
[0092] Furthermore, when TGF-β1 was applied to LP-9, a normal human mesothelial cell line, the cell morphology changed from cobblestone-like to spindle-like due to mesenchymal transition, promoting motility (Figure 7).
[0093] Immunohistochemical staining using antibodies labeling calretinin (a mesothelial cell marker) and LRRN4 was performed on fallopian tube serosa tissue specimens from patients with ovarian cancer, endometriosis, and uterine fibroids. The respective proteins were labeled brown, and the cell nuclei were labeled blue. Calretinin-positive mesothelial cells were present in the fallopian tube serosa, and LRRN4 expression was confirmed. Surface mesothelial cells in the fallopian tubes of patients with benign uterine fibroids were generally very flat and tile-shaped, and LRRN4 was deeply stained (arrow). On the other hand, mesothelial cells from patients with ovarian cancer and endometriosis were generally significantly irregular, with round epithelial cell nuclei and faint LRRN4 staining (arrowhead). These results indicated that normal mesothelial cells without epithelial-mesenchymal transition (EMT) have a shape characteristic of epithelial cells (flat tile-like), whereas mesothelial cells from endometriosis patients have a shape characteristic of mesenchymal cells (spindle-like) due to EMT. Furthermore, these results suggest a correlation between EMT and decreased LRRN4 expression in mesothelial cells from ovarian cancer and endometriosis patients. It has been reported that in benign diseases such as uterine fibroids, which contain normal mesothelial cells, the peritoneum is pale red to milky white and slimy, whereas in patients with advanced ovarian cancer or severe endometriosis, where mesothelial cells have undergone EMT, the peritoneum appears redder and rougher. These findings suggest that the macroscopic observation results and microscopic immunostaining results are consistent.
[0094] Western blotting analysis using an LRRN4-specific antibody also confirmed that LRRN4 protein expression was reduced in cells undergoing EMT (Figure 9). The results in Figures 7, 8, and 9 newly revealed that when the level of LRRN4 expression in mesothelial cells is reduced due to EMT, morphological changes in mesothelial cells are accompanied by enhanced motility.
[0095] When hypoxic conditions were applied to non-lesioned human peritoneal mesothelial cells (HPMCs), Western blotting analysis using an LRRN4-specific antibody confirmed that LRRN4 protein expression was reduced (Figure 10). Hypoxia is known to be a type of cellular stress, reflecting conditions such as ischemia in chronic inflammatory states. As shown in Figure 10, hypoxia was confirmed to induce mesenchymal transition in mesothelial cells, similar to stimulation with TGF-β1.
[0096] Quantification of LRRN4 mRNA expression by real-time PCR revealed that stimulation with TGF-β1 induced epithelial-mesenchymal transition in mesothelial cells, resulting in a significant decrease in LRRN4 mRNA expression along with a decrease in E-cadherin expression and an increase in αSMA expression. However, administration of vitamin D (calcitriol) in addition to TGF-β1 stimulation induced mesenchymal-epithelial transition in mesothelial cells, and LRRN4 mRNA expression levels were restored to the same level as in the control (Figure 11).
[0097] When cancer cells from peritoneal disseminated tumors were co-cultured with peritoneal mesothelial cells, mesenchymal transition was induced in the control. On the other hand, when cancer cells and peritoneal mesothelial cells were co-cultured and vitamin D (calcitriol) was added, mesenchymal transition occurred in the mesothelial cells, which were observed to change to an epithelial-like morphology compared to the control. Therefore, it is thought that vitamin D (calcitriol) induces mesenchymal-epithelial transition in mesothelial cells (Figure 12).
[0098] By examining the expression or activity level of LRRN4 before and after treatment of mesothelial cells with a candidate substance and observing the change, it is possible to evaluate how the candidate substance affects peritoneal dissemination of ectopic cells. As described above, when mesothelial cells are normal mesothelial cells, the expression or activity level of LRRN4 is high. Therefore, if the expression or activity level of LRRN4 decreases after treatment with a candidate substance, the candidate substance can be selected as one that exacerbates peritoneal dissemination of ectopic cells. As an example, in the results of Test Example 5 above, TGF-β1 is selected as a substance that exacerbates peritoneal dissemination of ectopic cells. On the other hand, when mesothelial cells are mesothelial cells in which mesenchymal transition has been induced, the expression or activity level of LRRN4 is low. If the expression or activity level of LRRN4 increases after treatment of such mesothelial cells with a candidate substance, the candidate substance can be selected as one that prevents or ameliorates peritoneal dissemination of ectopic cells. As an example, in the results of Test Example 5 above, vitamin D (calcitriol) is selected as a substance that prevents or improves peritoneal dissemination of ectopic cells.
[0099] Test Example 6: Effect of administration of candidate substance on mesenchymal transition and peritoneal dissemination of ectopic cells When TGF-β1 was administered to the above mesothelial cell line together with the candidate substance (vitamin D (calcitriol) (also referred to as VD)), the induction of mesenchymal transition by TGF-β1 was suppressed ( FIG. 13 , upper panel).
[0100] Furthermore, when the mesothelial cell line was treated with 10 ng / mL of TGF-β1 in RPMI-1640 medium supplemented with 1% FBS for 3 days in the presence of the candidate substance and then co-cultured with cancer cells, a type of ectopic cell, it was confirmed that cancer cell adhesion was promoted, whereas cancer cell adhesion was suppressed in the absence of the candidate substance (Figure 13, bottom panel).
[0101] Ectopic endometrial epithelial-derived immortalized cell line (Ishikawa) was spread onto normal mesothelial cells and mesothelial cells stimulated with TGF-β1 to undergo mesenchymal transition (MT), and the number of adherent cells was counted. The results showed that more ectopic cells adhered to mesothelial cells stimulated with TGF-β1 than to normal mesothelial cells. These results demonstrated that ectopic endometrial cells adhere more readily to mesothelial cells undergoing MT. This suggests that MT-induced mesothelial transition, accompanied by decreased LRRN4 expression, may play a role in the progression of endometriosis due to ectopic endometrial engraftment (Figure 14).
[0102] Mice were intraperitoneally administered 10 ng / mL of TGF-β1 for 3 days, and the morphology of the peritoneal surface was observed under a scanning electron microscope, revealing disruption of the microvilli structure and roughening of intercellular adhesion (Figure 15, left). When GFP-labeled ES-2 cells (ovarian cancer cell line) were further intraperitoneally administered as ectopic cells, mesenchymal transition of mesothelial cells was induced, confirming peritoneal dissemination of ovarian cancer cells (black line area) (Figure 15, right).
[0103] On the other hand, when mice were intraperitoneally administered 10 ng / mL of TGF-β1 and 50 μM of the candidate substance (vitamin D (calcitriol)) for 3 days and then intraperitoneally administered GFP-labeled ES-2 cells (ovarian cancer cell line) as ectopic cells, mesenchymal transition of mesothelial cells was suppressed, and suppression of peritoneal dissemination of ovarian cancer cells was confirmed (Figure 15, right).
[0104] As shown in the results of the above test examples, the expression or activity level of LRRN4 in mesothelial cells can be confirmed, and candidate substances that can increase the expression or activity level of LRRN4 can be selected as those that are effective in preventing or ameliorating diseases or symptoms caused by peritoneal dissemination of ectopic cells.
[0105] Furthermore, as shown in the results of the above test example, when the expression or activity level of LRRN4 in mesothelial cells obtained from a subject is confirmed and compared with the expression or activity level of LRRN4 in normal mesothelial cells, if the expression or activity level of LRRN4 in mesothelial cells obtained from the subject is lower, it can be determined that the subject is at high risk of developing or aggravating a disease or symptom due to peritoneal dissemination of ectopic cells.
Claims
1. A method for screening for a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells, comprising the steps of: (a) treating mesothelial cells with a candidate substance; (b) confirming the expression or activity level of LRRN4 (Leucine Rich Repeat Neuronal 4) in the mesothelial cells; and (c) selecting the candidate substance as a substance for preventing or ameliorating a disease or symptom caused by peritoneal dissemination of ectopic cells when the expression or activity level of LRRN4 in the mesothelial cells increases compared to before the treatment.
2. The method according to claim 1, wherein the disease or symptom caused by peritoneal dissemination of ectopic cells is metastasis of cancer cells to the peritoneum.
3. The method according to claim 2, wherein the metastasis of cancer cells to the peritoneum occurs in at least one solid cancer selected from the group consisting of ovarian cancer, gastric cancer, colon cancer, and pancreatic cancer.
4. The method according to claim 1, wherein the disease or symptom caused by peritoneal seeding of ectopic cells is a disease or symptom caused by adhesion or growth of endometrial cells to the peritoneum.
5. The method according to claim 4, wherein the disease or symptom caused by adhesion or growth of endometrial cells to the peritoneum is menstrual pain, primary dysmenorrhea, secondary dysmenorrhea, or endometriosis.
6. The method of claim 1, wherein the mesothelial cells have lower expression of LRRN4 compared to normal mesothelial cells.
7. The method according to claim 1, wherein the mesothelial cells are normal mesothelial cells in which mesenchymal transition has been induced by administering a cytokine to the normal mesothelial cells.
8. The method according to claim 7, wherein the cytokine is TGF-β.
9. A method for predicting the risk of developing or aggravating a disease or symptom caused by peritoneal dissemination of ectopic cells, comprising the steps of: (a) confirming the expression or activity level of LRRN4 in mesothelial cells obtained from a subject; and (b) determining that the subject has a high risk of developing or aggravating a disease or symptom caused by peritoneal dissemination of ectopic cells if the expression or activity level of LRRN4 in mesothelial cells obtained from the subject is lower compared to the expression or activity level of LRRN4 in normal mesothelial cells.
Citation Information
Patent Citations
Application of ketorolac to preparation of medicine for preventing or treating postoperative recurrence of endometriosis
CN112587523A
Method for inhibiting peritoneal metastasis caused by gastric cancer cells
US20140162950A1
Method for testing peritoneal dissemination of gastric cancer by SYT13, SYT8, and ANOS1 expression levels, test kit, molecularly targeted therapeutic screening method, and therapeutic agent
WO2016143697A1
Composition for cancer treatment
WO2022265092A1
